Stocknear Logo Stocknear
/
Popular
  • KO Coca Cola Company Stock
  • TSLA Tesla Inc Stock
  • AMD Advanced Micro Devices Stock
  • SPY SPDR S&P 500 ETF Trust ETF
  • NVDA Nvidia Stock
    • Login

    Amicus Therapeutics Inc.

    NASDAQ: FOLD · Real-Time Price · USD
    5.75
    -0.18 (-3.04%)
    At close: Jun 30, 2025, 3:32 PM

    Amicus Therapeutics Statistics

    Share Statistics

    Amicus Therapeutics has 307.93M shares outstanding. The number of shares has increased by 3.73% in one year.

    Shares Outstanding

    n/a
    		 307.93M

    Shares Change (YoY)

    n/a
    		 3.73%

    Shares Change (QoQ)

    n/a
    		 2.82%

    Owned by Institutions (%)

    n/a
    		 99.99%

    Shares Floating

    n/a
    		 297.12M

    Failed to Deliver (FTD) Shares

    n/a
    		 557,348

    FTD / Avg. Volume

    n/a
    		 11.26%

    Short Selling Information

    The latest short interest is 20.9M, so 6.79% of the outstanding shares have been sold short.

    Short Interest

    n/a
    		 20.9M

    Short % of Shares Out

    n/a
    		 6.79%

    Short % of Float

    n/a
    		 6.83%

    Short Ratio (days to cover)

    n/a
    		 4.88

    Valuation Ratios

    The PE ratio is -51.1 and the forward PE ratio is 21.87. Amicus Therapeutics's PEG ratio is 0.79.

    PE Ratio

    n/a
    		 -51.1

    Forward PE

    n/a
    		 21.87

    PS Ratio

    n/a
    		 5.43

    Forward PS

    n/a
    		 1.4

    PB Ratio

    n/a
    		 14.78

    P/FCF Ratio

    n/a
    		 -76.57

    PEG Ratio

    n/a
    		 0.79
    Financial Ratio History

    Enterprise Valuation

    Currently the Enterprise Value (EV) is not available for Amicus Therapeutics.

    EV / Sales

    n/a
    		 n/a

    EV / EBITDA

    n/a
    		 n/a

    EV / EBIT

    n/a
    		 n/a

    EV / FCF

    n/a
    		 n/a

    Financial Position

    The company has a current ratio of 3.39, with a Debt / Equity ratio of 2.29.

    Current Ratio

    n/a
    		 3.39

    Quick Ratio

    n/a
    		 2.6

    Debt / Equity

    n/a
    		 2.29

    Debt / EBITDA

    n/a
    		 15.1

    Debt / FCF

    n/a
    		 -11.85

    Interest Coverage

    n/a
    		 0.5

    Financial Efficiency

    Return on Equity is n/a and Return on Invested Capital is n/a.

    Return on Equity

    n/a
    		 n/a

    Return on Assets

    n/a
    		 n/a

    Return on Invested Capital

    n/a
    		 n/a

    Revenue Per Employee

    n/a
    		 $1,058,707.41

    Profits Per Employee

    n/a
    		 $-112,436.87

    Employee Count

    n/a
    		 499

    Asset Turnover

    n/a
    		 0.67

    Inventory Turnover

    n/a
    		 0.45

    Taxes

    Income Tax

    n/a
    		 27.35M

    Effective Tax Rate

    n/a
    		 -95.11%

    Stock Price Statistics

    The stock price has increased by -40.12% in the last 52 weeks. The beta is 0.53, so Amicus Therapeutics's price volatility has been higher than the market average.

    Beta

    n/a
    		 0.53

    52-Week Price Change

    n/a
    		 -40.12%

    50-Day Moving Average

    n/a
    		 6.31

    200-Day Moving Average

    n/a
    		 8.9

    Relative Strength Index (RSI)

    n/a
    		 46.34

    Average Volume (20 Days)

    n/a
    		 4,948,743

    Income Statement

    In the last 12 months, Amicus Therapeutics had revenue of 528.29M and earned -56.11M in profits. Earnings per share was -0.18.

    Revenue

    n/a
    		 528.29M

    Gross Profit

    n/a
    		 475.35M

    Operating Income

    n/a
    		 24.88M

    Net Income

    n/a
    		 -56.11M

    EBITDA

    n/a
    		 29.39M

    EBIT

    n/a
    		 20.84M

    Earnings Per Share (EPS)

    n/a
    		 -0.18
    Full Income Statement

    Balance Sheet

    The company has 213.75M in cash and 443.64M in debt, giving a net cash position of -229.89M.

    Cash & Cash Equivalents

    n/a
    		 213.75M

    Total Debt

    n/a
    		 443.64M

    Net Cash

    n/a
    		 -229.89M

    Retained Earnings

    n/a
    		 -2.74B

    Total Assets

    n/a
    		 789.84M

    Working Capital

    n/a
    		 357.91M
    Full Balance Sheet

    Cash Flow

    In the last 12 months, operating cash flow was -33.89M and capital expenditures -3.55M, giving a free cash flow of -37.44M.

    Operating Cash Flow

    n/a
    		 -33.89M

    Capital Expenditures

    n/a
    		 -3.55M

    Free Cash Flow

    n/a
    		 -37.44M

    FCF Per Share

    n/a
    		 -0.12
    Full Cash Flow Statement

    Margins

    Gross margin is 89.98%, with operating and profit margins of 4.71% and -10.62%.

    Gross Margin

    n/a
    		 89.98%

    Operating Margin

    n/a
    		 4.71%

    Pretax Margin

    n/a
    		 -5.44%

    Profit Margin

    n/a
    		 -10.62%

    EBITDA Margin

    n/a
    		 5.56%

    EBIT Margin

    n/a
    		 4.71%

    FCF Margin

    n/a
    		 -7.09%

    Dividends & Yields

    FOLD does not appear to pay any dividends at this time.

    Dividend Per Share

    n/a
    		 n/a

    Dividend Yield

    n/a
    		 n/a

    Dividend Growth (YoY)

    n/a
    		 n/a

    Payout Ratio

    n/a
    		 n/a

    Earnings Yield

    n/a
    		 n/a

    FCF Yield

    n/a
    		 n/a
    Dividend Details

    Analyst Forecast

    The average price target for FOLD is $17, which is 186.2% higher than the current price. The consensus rating is "Buy".

    Price Target

    n/a
    		 $17

    Price Target Difference

    n/a
    		 186.2%

    Analyst Consensus

    n/a
    		 Buy

    Analyst Count

    n/a
    		 10
    Stock Forecasts

    Fair Value

    There are several formulas that can be used to estimate the intrinsic value of a stock.

    Lynch Fair Value

    n/a
    		 n/a

    Lynch Upside

    n/a
    		 n/a

    Graham Number

    n/a
    		 n/a

    Graham Upside

    n/a
    		 n/a

    Scores

    Altman Z-Score

    n/a
    		 -1.58

    Piotroski F-Score

    n/a
    		 5

    Add to Watchlist